Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)

NCT: NCT07684313 · NOT_YET_RECRUITING

NCT IDNCT07684313
StatusNOT_YET_RECRUITING
Start Date2026-08
Completion2034-12
SponsorEdwards Lifesciences (INDUSTRY)
First posted
Last updated

Brief Summary

TRIBLAZE is a prospective, observational, single-arm, multicenter study designed to collect real-world clinical outcomes in a minimum of 75 participants who will receive the Edwards Lifesciences TRIFORMIS RESILIA surgical tricuspid heart valve, Model 11300T.

Frequently Asked Questions

What is TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)?

TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study) is a clinical trial registered under NCT07684313. Current status: NOT_YET_RECRUITING.

What is the status of NCT07684313?

The current status of NCT07684313 (TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)) is: NOT_YET_RECRUITING.

When did TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study) start?

TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study) started on 2026-08.

Related Devices

PMA P860057replacement Heart-valveEdwards Lifesciences, LLC K251982Edwards MC3 Tricuspid annuloplasty ring (4900)Edwards Lifesciences, LLC PMA P150036heart-valve, non-allograft tissueEdwards Lifesciences, LLC PMA P150048heart-valve, non-allograft tissueEdwards Lifesciences, LLC

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑